CAG Webinar Program
This program covers a wide array of GI-focused topics with outlined learning objectives to meet the educational needs of CAG members, including Adult and Pediatric Gastroenterologists, Basic Scientists, and Trainees.
Watching recordings is considered a Section 2: Individual Learning activity by the Royal College of Physicians and Surgeons of Canada Maintenance of Certification program. Each recording is eligible for .5 hours of Section 2 credits.
Webinars are available to CAG members. Log in to your MyCAG account to start watching.
Already logged in? Watch Now. Not a CAG member? Become one!
Available webinars:
Get IBD Update webinar slides
Explore key abstracts and review Canadian expert commentary on the significance of the data to Canadian clinical practice. You can search by abstract, disease, or author, so you can easily find, download, or share high quality slides with your colleagues.
Visit IBDupdate.org and enter access code: ibd
CAG/AbbVie/Amgen/Ferring/J&J/Pfizer/Pendopharm/Takeda
IBD Update Post ECCO 2025
Featuring:
- Dr. Waqqas Afif, McGill University
- Dr. Vipul Jairath, Western University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Reena Khanna, Western University
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with AbbVie Corporation, Amgen, Ferring Canada, J&J Innovative Medicine, Pfizer Canada, Pendopharm, and Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/AbbVie/J&J/Pfizer/Takeda
IBD Update Post UEGW 2024
Featuring:
- Dr. John Marshall, McMaster University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Waqqas Afif, McGill University
- Dr. Sally Lawrence, BC Children's Hospital
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with AbbVie Corporation, J&J Innovative Medicine, Pfizer Canada, Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Takeda
IBD Update Post DDW 2024
Featuring:
- Dr. Aline Charabaty, Johns Hopkins School of Medicine
- Dr. Waqqas Afif, McGill University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Cynthia Seow, University of Calgary
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Takeda
IBD Update from ECCO 2024
Featuring:
- Dr. Brian Feagan, Western University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Waqqas Afif, McGill University
- Dr. Reena Khanna, Western University
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Janssen
AI in IBD and Beyond
Featuring:
- Mark Borgaonkar, MD, MSc, FRCPC, FACG, CAGF
- Alan Barkun, MD, CM, FRCPC, FACP, FACG, AGAF, MSc
- Peter Bossuyt, MD, PhD
- Vipul Jairath, MBChB, DPhil
- Kerri Novak, MD, FRCPC
- Michael F. Byrne, MD, MA, FRCPC, MRCP
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe the use of AI in IBD risk stratification and prognostication
- Integrate AI into IBD scoring systems in their clinical practice
- Employ AI to help personalize their approach to patient care
CAG/Incyte
CHOLABORATE: Updated Approaches to Cholangiocarcinoma Management
Featuring:
- Avijit Chatterjee, MD
- Pushpa Sathya, MD
- Michael Carter, MD
- Hatim Karachiwala, MD
Learning Objectives
Upon completion of this program, participants will be able to:
- Explain the diagnostic process and challenges for patients with cholangiocarcinoma (CCA)
- Describe methods to detect genomic abnormalities in CCA and the tissue requirements to ensure successful genomic testing
- Apply knowledge of the evolving treatment options for patients with CCA in clinical practice
CAG/Pfizer
Settling Behaviour in IBD
Featuring:
- Mark Borgaonkar, MD, MSc, FRCPC
- Yvette Leung, MD, FRCPC
Learning Objectives
Upon completion of this program, participants will be able to:
- Identify patients with IBD who exhibit settling behaviour with their treatment
- Identify barriers and areas of discordance in both communication and treatment priorities between patients and gastroenterologists
- Apply appropriate treatment strategies and tools aimed at addressing settling behaviour in patients with inadequately controlled IBD through case discussion